Your session is about to expire
← Back to Search
MT-6402 for Solid Cancers
Study Summary
This trial is for a new cancer treatment called MT-6402. It will test how well it works and what side effects it has in people with advanced solid cancer that is positive for PD-L1.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer's PD-L1 levels were checked with a specific test.I have lasting side effects from previous immunotherapy.I have not had radiation therapy in the last 4 weeks.My NSCLC has returned or spread and standard treatments aren't suitable for me.I have taken a pregnancy test within the last 3 days and it was negative.I haven't taken any approved or experimental drugs for my condition in the last 4 weeks.I have severe lung inflammation not caused by an infection.I am not pregnant or breastfeeding.I am over 18 with a PD-L1 positive advanced cancer that cannot be treated with standard methods.I am over 18, have advanced cancer with PD-L1, and standard treatments aren't suitable for me.You must have at least one tumor that can be measured by a specific set of criteria called RECIST 1.1.I am 18 or older with a confirmed advanced cancer that cannot be treated with surgery or standard treatments.I have a PD-L1 positive tumor, have tried treatments, and standard options aren't suitable for me.I am 18 or older with a type of cancer that cannot be removed by surgery and does not respond well to standard treatments.I have not had major surgery within the last 28 days.My cancer in the head or neck area cannot be treated with standard methods, or such treatments are not suitable for me.I am eligible for both parts A and B of the study.I have an autoimmune disease that hasn't needed treatment in the last 2 years.My bone marrow is functioning well.My kidneys work well, with a creatinine clearance rate of 50 mL/min or higher.My disease can be measured or seen on tests.My NSCLC has returned or spread and standard treatments are not suitable for me.I have lost more than 10% of my weight without trying in the last 2 months.I have or had another type of cancer.I haven't taken specific cancer drugs like atezolizumab, durvalumab, or avelumab in the months before starting MT-6402.I have received a transplant from a donor.I have been treated with immune checkpoint inhibitors for my cancer.I have a PD-L1 positive tumor that has returned or didn't respond to treatment, and standard treatments aren't suitable for me.I have a history of serious heart problems.My liver functions are within the required range for the trial.I am not receiving any cancer treatment except for palliative care on specific areas.I am fully active or restricted in physically strenuous activity but can do light work.You don't have any tumors that can be easily biopsied or you don't want to undergo a biopsy.I don't have tissue from my cancer that has spread, or I can't or won't consent to a biopsy.I'm sorry, but "Part A" does not provide enough context for me to understand what criterion you are referring to. Could you please provide more information or context?There is no specific information provided to rewrite this criterion. Please provide more context or details.My cancer has returned or spread and cannot be treated with standard methods.My cancer can be measured or seen on tests.I am taking more than 10 mg/day of steroids.
- Group 1: Other relapsed/refractory PD-L1 positive solid tumors
- Group 2: PD-L1 Positive SCCHN
- Group 3: PD-L1 Positive NSCLC
- Group 4: PD-L1 positive advanced cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has MT-6402 been sanctioned by the FDA?
"With limited data supporting safety and efficacy, MT-6402 received a score of 1."
What number of health care centers are running this experiment in the city?
"Currently, this medical trial is recruiting patients from 8 different sites located around the United States. These locations encompass Saint Louis, Chicago, and Los Angeles in addition to other cities that are geographically nearby. If you would like to participate in the study it may be beneficial to select a site closeby so as to reduce any necessary travel requirements."
How many individuals can take part in this experimental research?
"This clinical trial necessitates 138 participants that meet the inclusion requirements. People can partake in this study at Washington University School of Medicine - St. Louis, Saint Louis and Comprehensive Care and Research Center - Chicago, Illinois."
Are there any open recruitment opportunities for this investigation?
"Per information on clinicaltrials.gov, this experiment is actively seeking participants as of now - the posting date was May 27th 2021 and it was last updated February 25th 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger